60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Phase 2positiveTafenoquinePositive

AI Analysis

Summary

60 Degrees Pharmaceuticals received a positive recommendation from the Data Safety Monitoring Board for its B-FREE Phase 2 study of tafenoquine for chronic babesiosis, with no safety concerns identified. The DSMB has recommended continuing the trial.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Data Safety Monitoring Board recommends continuing B-FREE Phase 2 study with no safety concerns identified

Importance:6/10

Sentiment:

0.80

Phase 2 dataDSMB recommendationsafety clearancerare diseasebabesiosis

Read the original article

Published by GlobeNewswire Clinical Studies on July 1, 2026 12:02 PM

Read Original